Company: SHPH
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001493152-25-009106
Chunk: 30

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-05
Form: S-1/A
Chunk 30
---
 shares
of common stock. The issuance of new shares of common stock could result in resales of our shares of common stock by our current shareholders
concerned about the potential ownership dilution of their holdings. Furthermore, in the future, we may issue additional shares of common
stock or other equity or debt securities exercisable or convertible into shares of common stock. Any such issuance could result in substantial
dilution to our existing shareholders and could cause our stock price to decline.

| 16 |

<div align='center'>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and the documents included herein contain forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this prospectus or incorporated by reference in this prospectus and the documents included herein are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “project,” “continue,” “potential,” “ongoing” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

| ● | the                                                                                                                                            
 initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and INDs,          
 NDAs other regulatory submissions;                                                                                                             |
| ● | our                                                                                                                                            
 expected dependence on third party collaborators for developing, obtaining regulatory approval for and commercializing product candidates;     |
| ● | our                                                                                                                                            
 receipt and timing of any milestone payments or royalties under any research collaboration and license agreement we enter into;                |
| ● | our                                                                                                                                            
 ability to identify and develop product candidates;                                                                                            |
| ● | our                                                                                                                                            
 or a collaborator’s ability to obtain and maintain regulatory approval of any of our product candidates;                                       |
| ● | the                                                                                                                                            
 rate and degree of market acceptance of any approved products candidates;                                                                      |
| ● | the                                                                                                                                            
 commercialization of any approved product candidates;                                                                                          |
| ● | our                                                                                                                                            
 ability to establish and maintain additional collaborations and retain commercial rights for our product candidates subject to collaborations; |
| ● | the                                                                                                                                            
 implementation of our business model and strategic plans for our business, technologies and product candidates;                                |
| ● | our                                                                                                                                            
 estimates of our expenses, ongoing losses, future